December 10, 2010 (San Antonio, Texas) — "Nobody knows whether patients with HER2-positive ductal carcinoma in situ (DCIS) have increased local recurrence of disease," said Lia Halasz, MD, a radiation ...

SAN ANTONIO ― Oncologists can now offer postmenopausal women with ductal carcinoma in situ (DCIS) two options for prevention of breast cancer recurrence: anastrozole (Arimidex, AstraZeneca ...

In this phase 3 trial, researchers aimed to study the efficacy of tumor bed boost and moderately hypofractionated whole breast irradiation in patients with non-low-risk DCIS.

SAN ANTONIO – Patients with low-risk ductal carcinoma in situ (DCIS) who skipped adjuvant radiotherapy after breast-conserving surgery had comparable five-year outcomes to those with high-risk DCIS ...

SAN ANTONIO – For patients with “good-risk” ductal carcinoma in situ (DCIS) who underwent breast- conserving surgery and did not receive radiotherapy, tamoxifen significantly decreased the risk of ...

The incidence of invasive breast cancer after conservative treatment for ductal carcinoma in situ (DCIS) decreased by more than 50% over the past 30 years, data from a Dutch cancer registry showed.

Patients with low-risk ductal carcinoma in situ (DCIS) who skipped adjuvant radiotherapy after breast-conserving surgery had comparable five-year outcomes to those with high-risk DCIS who received ...

SAN ANTONIO -- Active monitoring for low-risk ductal carcinoma in situ (DCIS) did not lead to a higher rate of ipsilateral invasive cancer versus guideline-recommended treatment, the randomized COMET ...

A "watch-and-wait" strategy might be the best option for some women with early-stage, low-risk breast cancer. Photo by Adobe Stock/HealthDay News A "watch-and-wait" strategy might be the best option ...

Delaying radiation therapy too long after surgery significantly increases the risk of recurrent tumors in women treated for very early, or what is referred to as "stage 0," breast cancer, according to ...

Soon after her diagnosis, Storm’s physician team ordered PreludeDx’s DCISionRT®, the only risk assessment test that predicts radiation therapy (RT) benefit in DCIS patients, to be run on her tumor ...

Maintenance Rituximab After Cyclophosphamide, Vincristine, and Prednisone Prolongs Progression-Free Survival in Advanced Indolent Lymphoma: Results of the Randomized Phase III ECOG1496 Study A ...